Ọgwụ ọhụrụ maka edema ụbụrụ

A Jide Free Ntọhapụ 1 | eTurboNews | eTN

Simcere Pharmaceutical Group na Aeromics, Inc. taa mara ọkwa na Simcere doziri ihe ọmụmụ mbụ na SIM0307 (AER-271) Phase I nke emere na ụlọ ọgwụ Beijing Tiantan.

Nke a otu etiti, randomized, okpukpu abụọ kpuru, placebo na-achịkwa usoro ọmụmụ ụlọ ọgwụ na-eme atụmatụ ịdebanye aha isiokwu 56 iji nyochaa nnabata, nchekwa na njirimara ọgwụ mgbe otu / ọtụtụ nchịkwa na ndị ọrụ afọ ofufo China siri ike. Prọfesọ Wang Yongjun, Dean nke ụlọ ọgwụ Beijing Tiantan, Mahadum Ahụike Capital bụ onye isi nyocha. Emere ọmụmụ ihe a n'ihu ọha na Disemba 2, 2021, yana usoro izizi nke 4 n'ime otu ọgwụ izizi emechara na 8th nke Disemba.

"Mmalite nke dosing na Simcere's first clinical study of SIM0307 bụ nzọụkwụ ọzọ dị mkpa na-aga n'ihu na mmepe zuru ụwa ọnụ nke AER-271 ka anyị na-achọ iguzobe ọgwụgwọ dị mkpa, bara uru maka nnukwu ọrịa strok ischemic," Mike Gresser, Onye isi ndị ọkà mmụta sayensị nke Aeromics kwuru. . Gresser gbakwụnyere, "tPA na ọgwụgwọ thrombolytic ndị ọzọ na-ebute reperfusion, nke dị mkpa, ma na-ebutekarị mmerụ ahụ. A na-atụ anya ọgwụgwọ na AER-271 n'akụkụ ọgwụgwọ thrombolytic ga-enyere aka belata edema site n'itinye aka na mmalite nke usoro mkpali nke sitere na reperfusion site na tPA, thrombectomy ntuziaka na ọgwụgwọ thrombolytic ndị ọzọ.

Aeromics na Simcere abanyela na mmekorita ya na nkwekọrịta ikike pụrụiche na Nọvemba 2019 maka AER-271, a na-emepe usoro ọgwụgwọ mgbochi edema maka ọgwụgwọ ọrịa strok na ihe ngosi ndị ọzọ na Greater China (China China, Hong Kong, Macau na Taiwan). Dabere na nkwekọrịta ahụ, Simcere ga-ahụ maka mmepe ụlọ ọgwụ na azụmaahịa nke AER-271 na Greater China. N'April 2021, China National Medical Products Administration (NMPA) kwadoro nnwale ụlọ ọgwụ nke SIM0307 maka ngosipụta nke edema cerebral mgbe nnukwu ọrịa strok gachara.

"Obi dị anyị ụtọ ịhụ SIM0307 ruru ihe dị mkpa na China." kwuru Dr. Renhong Tang, Onye isi nchịkwa na onye isi oche onye isi oche nke Simcere, "Ọganihu ngwa ngwa nke molekul a na-emesi ike jikọtara ọnụ ọgụgụ ụwa nke Aeromics na Simcere R & D, mmepe ụlọ ọgwụ, mmepụta ihe, na ịzụ ahịa."

"Anyị na-aga n'ihu na-enwe ekele maka mmekọrịta anyị na Simcere ka ndị otu anyị na-arụkọ ọrụ ọnụ iji kwalite mmemme a. Ihe niile anyị kwenyere gbasara nyocha ha, mmepe na ike nrụpụta ha bụ eziokwu, yana ụdị imekọ ihe ọnụ nke otu ha karịrị ihe anyị tụrụ anya ya. Obi dị anyị ụtọ ịhụ ọganihu Simcere ka anyị na-akwado maka nnwale nke usoro ihe akaebe nke usoro IIa ebe a na United States." Thomas Zindrick, Onye isi oche Executive nke Aeromics kwuru.

Simcere's Executive Chairman & CEO, Mr. Jinsheng Ren kwubiri, "Anyị nwere mpako na anyị na-emepe emepe SIM0307 (AER-271), ka anyị na-asụgharị bayoloji na-emeri Nobel n'ime ọgwụgwọ bara uru maka ndị ọrịa na-arịa ọrịa nwere oke ọgwụgwọ nhọrọ. Na mgbakwunye, SIM0307 nwere ike imekọrịta ngwaahịa ndị ọzọ dị na Pọtụfoliyo CNS Simcere dị ka Sanbexin® nke nwere ike imeziwanye nsonaazụ nke ndị ọrịa strok. nke emepụtara iji tụgharịa asụsụ. Anyị na-atụ anya ọganihu na-akpali akpali n'ọdịnihu na mmekorita anyị na ndị otu Aeromics. "

IHE Ị GA-Ewepụ na edemede a:

  • "Nmalite nke dose na Simcere's first clinical study of SIM0307 bụ nzọụkwụ ọzọ dị mkpa na-aga n'ihu na mmepe zuru ụwa ọnụ nke AER-271 ka anyị na-achọ iguzobe ọgwụgwọ dị mkpa, bara uru maka nnukwu ọrịa strok ischemic."
  • Aeromics na Simcere abanyela na mmekorita ya na nkwekọrịta ikike pụrụiche na Nọvemba 2019 maka AER-271, a na-emepe usoro ọgwụgwọ mgbochi edema maka ọgwụgwọ ọrịa strok na ihe ngosi ndị ọzọ na Greater China (China China, Hong Kong, Macau na Taiwan).
  • Emere ọmụmụ ihe a n'ihu ọha na Disemba 2, 2021, yana usoro izizi nke 4 n'ime otu ọgwụ izizi emechara na 8th nke Disemba.

<

Banyere chepụtara

Linda Hohnholz

Onye nchịkọta akụkọ maka eTurboNews dabere na eTN HQ.

Idenye aha
Gwa nke
guest
0 Comments
Inline nzaghachi
Lee echiche niile
0
Ga-ahụ n'anya gị echiche, biko okwu.x
Kekọrịta ka...